RBC Capital Reiterates Rating on Alkermes plc $ALKS
Key Points
- RBC Capital now rates Alkermes plc ($ALKS) "buy" with a $56 target.
- RBC Capital's $56 price target implies 26.47% upside from Alkermes plc's ($ALKS) current $44.28 share price.
- The Street's average $ALKS price target is $56.
- $ALKS last traded around $44.28.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
RBC Capital reiterated its rating on Alkermes plc ($ALKS) to a "buy" rating in a recent research note and set a price target of $56, a 26.47% upside from the current price.
Alkermes plc Stock Down 6.6%
Shares of Alkermes plc ($ALKS) traded around $44.28 on Saturday, down 6.6% for the day.
Alkermes plc Earnings
Analysts Set New Price Targets
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Get Alkermes plc alerts
New 13F filings, insider trades, and analyst moves on $ALKS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.